Startup developing treatments for cancer raises nearly $2 million

Apr 08, 2015
From the St. Louis Business Journal

Euclises Pharmaceuticals, a biotech startup looking to develop treatments for cancer, has added approximately $700,000 to its Series A financing round, which has closed just shy of $2 million.

Euclises, which is developing selective cyclooxygenase-2 (“COX-2″) inhibitors to help treat cancer, reported raising $1.3 million of the round in September 2014 from a group of investors that included Cultivation Capital, the BioGenerator, Missouri Technology Corporation, the St. Louis Arch Angels, ABC Laboratories and the St. Louis County Port Authority’s Helix Fund.